MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...

Biocom California, the association representing the California life science industry, today announced that it appointed Kathryn Lowell, group vice president of global government affairs at BioMarin; ...

UK market access Peter Kuiper, general manager UK & Ireland at Sanofi Genzyme said the European Commission approval of Dupixent was a milestone for patients affected by the condition.

GdP has received scholarships from the ECTRIMS, the World Federation of Neurology and Novartis; funding for research from Biogen, Novartis and Roche; travel grants from Roche, Sanofi-Genzyme and Teva ...

Sanofi's Genzyme rare diseases division already sells another enzyme replacement therapy for Pompe disease based on the recombinant enzyme alglucosidase alfa – sold as Myozyme in Europe and ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

In September 2024, Sanofi announced the outcomes of Phase III clinical trials of its investigational oral brain-penetrant BTK inhibitor, tolebrutinib, aimed at treating multiple sclerosis (MS). These ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14,385.85 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...